Shane Thomas Gleason Sells 17,593 Shares of InspireMD (NYSE:NSPR) Stock

Posted by Donald Scott on Feb 4th, 2026

InspireMD, Inc. (NYSE:NSPR – Get Free Report) insider Shane Thomas Gleason sold 17,593 shares of InspireMD stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $1.62, for a total transaction of $28,500.66. Following the completion of the transaction, the insider directly owned 1,174,664 shares of the company’s stock, valued at $1,902,955.68. This trade represents a 1.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Shane Thomas Gleason also recently made the following trade(s):

On Monday, February 2nd, Shane Thomas Gleason sold 2,000 shares of InspireMD stock. The stock was sold at an average price of $1.60, for a total transaction of $3,200.00.
On Friday, January 30th, Shane Thomas Gleason sold 2,900 shares of InspireMD stock. The stock was sold at an average price of $1.63, for a total transaction of $4,727.00.
On Thursday, January 29th, Shane Thomas Gleason sold 5,000 shares of InspireMD stock. The shares were sold at an average price of $1.65, for a total value of $8,250.00.
On Wednesday, January 28th, Shane Thomas Gleason sold 12,395 shares of InspireMD stock. The stock was sold at an average price of $1.65, for a total value of $20,451.75.
On Tuesday, January 27th, Shane Thomas Gleason sold 4,781 shares of InspireMD stock. The stock was sold at an average price of $1.66, for a total value of $7,936.46.
On Thursday, January 22nd, Shane Thomas Gleason sold 8,411 shares of InspireMD stock. The shares were sold at an average price of $1.57, for a total value of $13,205.27.
On Tuesday, January 20th, Shane Thomas Gleason sold 2,955 shares of InspireMD stock. The stock was sold at an average price of $1.59, for a total value of $4,698.45.
On Friday, January 16th, Shane Thomas Gleason sold 2,250 shares of InspireMD stock. The shares were sold at an average price of $1.61, for a total value of $3,622.50.
On Thursday, January 15th, Shane Thomas Gleason sold 2,909 shares of InspireMD stock. The shares were sold at an average price of $1.58, for a total transaction of $4,596.22.

InspireMD Stock Up 0.6%

NSPR stock opened at $1.64 on Wednesday. The stock has a market cap of $69.49 million, a PE ratio of -2.19 and a beta of 0.72. The firm’s 50-day simple moving average is $1.82 and its 200 day simple moving average is $2.15. InspireMD, Inc. has a fifty-two week low of $1.51 and a fifty-two week high of $3.80.

Hedge Funds Weigh In On InspireMD

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Creative Planning bought a new stake in shares of InspireMD in the 2nd quarter worth $44,000. Uniting Wealth Partners LLC acquired a new position in InspireMD during the third quarter worth about $51,000. Citadel Advisors LLC raised its position in InspireMD by 45.0% in the third quarter. Citadel Advisors LLC now owns 37,954 shares of the company’s stock worth $91,000 after acquiring an additional 11,778 shares in the last quarter. Raymond James Financial Inc. raised its position in InspireMD by 28.9% in the second quarter. Raymond James Financial Inc. now owns 44,604 shares of the company’s stock worth $101,000 after acquiring an additional 10,000 shares in the last quarter. Finally, Vestia Personal Wealth Advisors lifted its holdings in InspireMD by 135.7% in the 3rd quarter. Vestia Personal Wealth Advisors now owns 42,425 shares of the company’s stock valued at $102,000 after acquiring an additional 24,425 shares during the last quarter. 44.78% of the stock is owned by institutional investors.

Trending Headlines about InspireMD

Here are the key news stories impacting InspireMD this week:

Positive Sentiment: Maxim Group initiated coverage with a “Buy” rating and a $6.00 price target (well above the current trading level), which appears to have driven investor interest and buying pressure. Read More.
Positive Sentiment: Recent filings and reports show several institutional investors increased positions in prior quarters (Rosalind Advisors, Nantahala, Aberdeen, Parkman, Velan), signalling continued institutional interest that can support the stock over time. Read More.
Neutral Sentiment: Company fundamentals/technical backdrop remains mixed: small market cap (~$69M), negative P/E, current price below the 50- and 200-day moving averages — factors that increase risk and may limit upside until clinical/commercial catalysts appear.
Negative Sentiment: Insider Shane Thomas Gleason has sold a material series of shares between Jan. 15 and Feb. 2 — roughly 61,000 shares at average prices in the ~$1.57–$1.66 range — which can create selling pressure and signal lack of insider accumulation into the rally. The sales are disclosed in SEC filings. Read More.

Wall Street Analyst Weigh In

Separately, Maxim Group assumed coverage on InspireMD in a research note on Monday. They set a “buy” rating and a $6.00 target price on the stock. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $5.00.

View Our Latest Stock Report on InspireMD

About InspireMD

(Get Free Report)

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.